EyePoint (EYPT) Total Non-Current Liabilities (2011 - 2026)
EyePoint (EYPT) reported Total Non-Current Liabilities of $57.7 million for Q1 2026, down 9.85% on a YoY basis from $64.0 million in Q1 2025, and little changed sequentially from $57.8 million in Q4 2025.
EyePoint (EYPT) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
EyePoint (EYPT) has 11 years of Total Non-Current Liabilities data on file, last reported at $57.7 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 9.85% year-over-year to $57.7 million; the trailing twelve-month figure through Mar 2026 stood at $57.7 million (down 9.85% YoY), and the FY2025 full-year result was $57.8 million, down 29.31% from the prior year.
- Total Non-Current Liabilities held at $57.7 million in Q1 2026, from $57.8 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $118.4 million in Q2 2023 to a low of $51.4 million in Q3 2025.
- A 5-year average of $78.5 million and a median of $81.5 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 45.33% in 2023 and sank 42.69% in 2025, its largest moves.
- Tracing EYPT's Total Non-Current Liabilities over 5 years: stood at $83.4 million in 2022, then advanced by 6.56% to $88.9 million in 2023, then decreased by 7.99% to $81.8 million in 2024, then fell by 29.31% to $57.8 million in 2025, then slipped by 0.18% to $57.7 million in 2026.
- Business Quant data shows EYPT's Total Non-Current Liabilities at $57.7 million in Q1 2026, $57.8 million in Q4 2025, and $51.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | EyePoint | 358.61 Mn | 136.07 Mn | 168,000.00 | 57.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.69 Mn |
| Dec 31, 2025 | 57.80 Mn |
| Sep 30, 2025 | 51.40 Mn |
| Jun 30, 2025 | 54.99 Mn |
| Mar 31, 2025 | 63.99 Mn |
| Dec 31, 2024 | 81.76 Mn |
| Sep 30, 2024 | 81.95 Mn |
| Jun 30, 2024 | 95.94 Mn |
| Mar 31, 2024 | 79.21 Mn |
| Dec 31, 2023 | 88.86 Mn |
| Sep 30, 2023 | 101.42 Mn |
| Jun 30, 2023 | 118.39 Mn |
| Mar 31, 2023 | 75.60 Mn |
| Dec 31, 2022 | 83.39 Mn |
| Sep 30, 2022 | 83.54 Mn |
| Jun 30, 2022 | 81.47 Mn |
| Mar 31, 2022 | 77.08 Mn |
| Dec 31, 2021 | 76.64 Mn |
| Sep 30, 2021 | 73.14 Mn |
| Jun 30, 2021 | 69.63 Mn |